Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003719 | 0.86 | NOD1 (0.48) | GLP1RNOD1 | |
| SCHEMBL30003728 | 0.80 | KMT2A (0.50) | GLP1RSIRT1NOD1L3MBTL1 | |
| SCHEMBL22994980 | 0.80 | NOD1 (0.37) | GLP1RNMT2NMT1SIRT6SIRT1 | |
| SCHEMBL22805060 | 0.78 | SIRT6 (0.46) | GLP1RNMT2NMT1SIRT6SIRT1 | |
| SCHEMBL22805061 | 0.78 | SIRT6 (0.46) | GLP1RNMT2NMT1SIRT6SIRT1 | |
| SCHEMBL23330800 | 0.75 | ALB (0.42) | SIRT6SIRT1TLR2NOD1L3MBTL1 | |
| SCHEMBL254806 | 0.75 | L3MBTL1 (0.43) | L3MBTL1 | |
| SCHEMBL18496714 | 0.75 | FOLH1 (0.64) | — | |
| SCHEMBL18516882 | 0.75 | FOLH1 (0.64) | — | |
| SCHEMBL18516883 | 0.75 | FOLH1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | GLP1R 712/4885NMT2 1466/4885NMT1 1618/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | GLP1R 712/4885NMT2 1466/4885NMT1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.